TVM Capital Life Science invests in transformative life science innovations, leveraging a two-pronged strategy: financing early-stage therapeutics through a partnership with Eli Lilly and investing in differentiated commercial-stage medtech, diagnostics, digital health, and late-stage therapeutics. The firm focuses on AI-driven drug development and building value through close partnerships with portfolio companies.
Bevorzugte Reifephase für die erste Finanzierung.
Breakthrough therapies, medical products, AI-driven drug development, early-stage therapeutics, commercial-stage medtech, diagnostics, and digital health
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
